Loading…
Capping Prescription Costs Act of 2018
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 7,393 other HR bills in the 115th — cohort avg 50d
Capping Prescription Costs Act of 2018 This bill caps the monthly prescription-drug cost-sharing permitted under qualified health plans and group health plans.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2018 · fourth_quarter · Pharmacy
S. 297, Increasing Competition in Pharmaceuticals Act (Collins-McCaskill) - prescription drug costs S. 974, CREATES Act (Leahy-Grassley) - access to generic drugs and biosimilars S. 1115, Making Pharmaceutical Markets More Competitive Act (Collins-McCaskill) - accelerated approval of generic therapies S. 1131, FAIR Drug Pricing Act (Baldwin-McCain) - transparency in prescription drug pricing S. 2553, Know the Lowest Price Act (Stabenow) - pharmacist-patient communications S. 2554, Patient Right to Know Drug Prices Act (Collins) - pharmacist-patient communications, reporting of biosimilar pay-for-delay settlements S. 3194, Capping Prescription Costs Act (Warren) - capping prescription copays S. 3738, Hatch-Waxman Integrity Act (Hatch) - inter partes review process S. 3792, Preserve Access to Affordable Generics and Biosimilars Act (Klobuchar-Grassley) - pay-for-delay settlements H.R. 749, Lower Drug Costs Through Competition Act (Schrader-Bilirakis) - prescription drug costs H.R. 1703, Medical Product Communication Act (Griffith) - off-label exchange of information H.R. 2026, Pharmaceutical Information Exchange Act (Guthrie) - pre-approval health care economic information to payors H.R. 2051, Fair Access for Safe and Timely Generics Act (McKinley-Welch) - access to generic drugs H.R. 2212, CREATES Act (Marino-Cicilline) - access to generic drugs and biosimilars H.R. 2439, FAIR Drug Pricing Act (Schakowsky) - transparency in prescription drug pricing H.R. 2562, Making Pharmaceutical Markets More Competitive Act (Kelly) - accelerated approval of generic therapies H.R. 2999, Patients' Access to Treatments Act (McKinley) - limiting cost sharing in specialty drug tiers H.R. 5247, Right to Try Act (Fitzpatrick) - use of unapproved investigational drugs by patients with life-threatening conditions H.R. 6142, Reducing Drug Waste Act (Doggett) - packaging of medications H.R. 6157, Defense-Labor-HHS-Education Appropriations Act (Granger) -pharmaceutical price transparency in DTC advertising H.R. 6340, Capping Prescription Costs Act (Rosen) - capping prescription copays H.R. 6478, Biosimilars Competition Act (Sarbanes) - reporting of pay-for-delay settlements H.R. 6576, Drug-Price Transparency in Communications Act (Schakowsky) - disclosure of drug prices in DTC advertising H.R. 6733, Know the Cost Act (Carter) - pharmacist-patient communications H.R. 7251, Hatch-Waxman Integrity Act (Flores) - inter partes review process Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $1,550,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
2018 · fourth_quarter · Health Issues
S. 92: Safe and Affordable Drugs from Canada Act S. 469: Affordable and Safe Prescription Drug Importation Act S. 1131/ H.R. 2439: FAIR Drug Pricing Act S. 1348: SPIKE Act of 2017 S. 1369/ H.R. 2974: Stop Price Gouging Act S. 1803/H.R. 4825, the Marijuana Effective Drug Studies (MEDS) Act S. 2076/H.R. 4256: BOLD Infrastructure for Alzheimer's Act S. 2406: Advancing Cutting Edge (ACE) Research Act S. 2478: End Taxpayer Subsidies for Drug Ads Act S. 2680: Opioid Crisis Response Act S. 2891: Fighting the Opioid Epidemic with Sunshine Act S. 3369/ HR 6689: Ensuring Lasting Smiles Act S. 3411/H.R. 6689: Affordable Medications Act S. 3657/ H.R. 6615: Traumatic Brain Injury Program Reauthorization Act S. 3686/ H.R. 3580: Protecting Student Athletes from Concussions Act H.R. 6: SUPPORT for Patients and Communities Act: Sections 6062 and 6111; Subtitle E H.R. 1776: Improving Access to Affordable Prescription Drugs Act H.R. 2077: Restoring the Patient's Voice Act H.R. 3391, Medical Marijuana Research Act of 2017 H.R. 4116: Transparent Drug Pricing Act H.R. 5634: Medical Cannabis Research Act H.R. 6340: Capping Prescription Costs Act Disclosure of drug prices in prescription drug direct-to-consumer advertising; Sustained fetal tissue research; Orphan Drug Act Reform; Interoperability, including for Qualified Clinical Data Registries; NIH funding including the BRAIN Initiative; Congressionally-Directed Medical Research Program funding; concussion related issues; loan repayment for pediatric specialists.
Client expense: $140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Health Issues
S. 92: Safe and Affordable Drugs from Canada Act S. 469: Affordable and Safe Prescription Drug Importation Act S. 1131/ H.R. 2439: FAIR Drug Pricing Act S. 1348: SPIKE Act of 2017 S. 1369/ H.R. 2974: Stop Price Gouging Act S. 2260 / H.R. 4733: Opioids and STOP Pain Initiative Act S. 2406: Advancing Cutting Edge (ACE) Research Act S. 2478: End Taxpayer Subsidies for Drug Ads Act S. 2680: Opioid Crisis Response Act S. 2891: Fighting the Opioid Epidemic with Sunshine Act S. 3369/ H.R. 6689: Ensuring Lasting Smiles Act S. 3411: Affordable Medications Act H.R. 6: SUPPORT for Patients and Communities Act: Sections 6062 and 6111; Subtitle E H.R. 1776: Improving Access to Affordable Prescription Drugs Act H.R. 2077: Restoring the Patient's Voice Act H.R. 4116: Transparent Drug Pricing Act H.R. 5634: Medical Cannabis Research Act H.R. 6340: Capping Prescription Costs Act Interoperability, including for Qualified Clinical Data Registries; Appropriations for the CDC National Neurological Conditions Surveillance System; Maintenance/expansion of Graduate Medical Education (GME); NIH funding including the BRAIN Initiative; Congressionally-Directed Medical Research Program funding; concussion related issues.
Client expense: $250,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Pharmacy
S. 297, Increasing Competition in Pharmaceuticals Act (Collins-McCaskill) - prescription drug costs S. 974, CREATES Act (Leahy-Grassley) - access to generic drugs and biosimilars S. 1115, Making Pharmaceutical Markets More Competitive Act (Collins-McCaskill) - accelerated approval of generic therapies S. 1131, FAIR Drug Pricing Act (Baldwin-McCain) - transparency in prescription drug pricing S. 2553, Know the Lowest Price Act (Stabenow) - pharmacist-patient communications S. 2554, Patient Right to Know Drug Prices Act (Collins) - pharmacist-patient communications, reporting of biosimilar pay-for-delay settlements S. 3194, Capping Prescription Costs Act (Warren) - capping prescription copays S. 3738, Hatch-Waxman Integrity Act (Hatch) - inter partes review process S. 3792, Preserve Access to Affordable Generics and Biosimilars Act (Klobuchar-Grassley) - pay-for-delay settlements H.R. 749, Lower Drug Costs Through Competition Act (Schrader-Bilirakis) - prescription drug costs H.R. 1703, Medical Product Communication Act (Griffith) - off-label exchange of information H.R. 2026, Pharmaceutical Information Exchange Act (Guthrie) - pre-approval health care economic information to payors H.R. 2051, Fair Access for Safe and Timely Generics Act (McKinley-Welch) - access to generic drugs H.R. 2212, CREATES Act (Marino-Cicilline) - access to generic drugs and biosimilars H.R. 2439, FAIR Drug Pricing Act (Schakowsky) - transparency in prescription drug pricing H.R. 2562, Making Pharmaceutical Markets More Competitive Act (Kelly) - accelerated approval of generic therapies H.R. 2999, Patients' Access to Treatments Act (McKinley) - limiting cost sharing in specialty drug tiers H.R. 5247, Right to Try Act (Fitzpatrick) - use of unapproved investigational drugs by patients with life-threatening conditions H.R. 6142, Reducing Drug Waste Act (Doggett) - packaging of medications H.R. 6157, Defense-Labor-HHS-Education Appropriations Act (Granger) -pharmaceutical price transparency in DTC advertising H.R. 6340, Capping Prescription Costs Act (Rosen) - capping prescription copays H.R. 6478, Biosimilars Competition Act (Sarbanes) - reporting of pay-for-delay settlements H.R. 6576, Drug-Price Transparency in Communications Act (Schakowsky) - disclosure of drug prices in DTC advertising H.R. 6733, Know the Cost Act (Carter) - pharmacist-patient communications H.R. 7251, Hatch-Waxman Integrity Act (Flores) - inter partes review process Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
Client expense: $1,540,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
2018 · fourth_quarter · Health Issues
S. 92: Safe and Affordable Drugs from Canada Act S. 469: Affordable and Safe Prescription Drug Importation Act S. 1131/ H.R. 2439: FAIR Drug Pricing Act S. 1348: SPIKE Act of 2017 S. 1369/ H.R. 2974: Stop Price Gouging Act S. 1803/H.R. 4825, the Marijuana Effective Drug Studies (MEDS) Act S. 2076/H.R. 4256: BOLD Infrastructure for Alzheimer's Act S. 2406: Advancing Cutting Edge (ACE) Research Act S. 2478: End Taxpayer Subsidies for Drug Ads Act S. 2680: Opioid Crisis Response Act S. 2891: Fighting the Opioid Epidemic with Sunshine Act S. 3369/ HR 6689: Ensuring Lasting Smiles Act S. 3411/H.R. 6689: Affordable Medications Act S. 3657/ H.R. 6615: Traumatic Brain Injury Program Reauthorization Act S. 3686/ H.R. 3580: Protecting Student Athletes from Concussions Act H.R. 6: SUPPORT for Patients and Communities Act: Sections 6062 and 6111; Subtitle E H.R. 1776: Improving Access to Affordable Prescription Drugs Act H.R. 2077: Restoring the Patient's Voice Act H.R. 3391, Medical Marijuana Research Act of 2017 H.R. 4116: Transparent Drug Pricing Act H.R. 5634: Medical Cannabis Research Act H.R. 6340: Capping Prescription Costs Act Disclosure of drug prices in prescription drug direct-to-consumer advertising; Sustained fetal tissue research; Orphan Drug Act Reform; Interoperability, including for Qualified Clinical Data Registries; NIH funding including the BRAIN Initiative; Congressionally-Directed Medical Research Program funding; concussion related issues; loan repayment for pediatric specialists.
Client expense: Not reported · Firm income: $140,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Health Issues
S. 92: Safe and Affordable Drugs from Canada Act S. 469: Affordable and Safe Prescription Drug Importation Act S. 1131/ H.R. 2439: FAIR Drug Pricing Act S. 1348: SPIKE Act of 2017 S. 1369/ H.R. 2974: Stop Price Gouging Act S. 2260 / H.R. 4733: Opioids and STOP Pain Initiative Act S. 2406: Advancing Cutting Edge (ACE) Research Act S. 2478: End Taxpayer Subsidies for Drug Ads Act S. 2680: Opioid Crisis Response Act S. 2891: Fighting the Opioid Epidemic with Sunshine Act S. 3369/ H.R. 6689: Ensuring Lasting Smiles Act S. 3411: Affordable Medications Act H.R. 6: SUPPORT for Patients and Communities Act: Sections 6062 and 6111; Subtitle E H.R. 1776: Improving Access to Affordable Prescription Drugs Act H.R. 2077: Restoring the Patient's Voice Act H.R. 4116: Transparent Drug Pricing Act H.R. 5634: Medical Cannabis Research Act H.R. 6340: Capping Prescription Costs Act Interoperability, including for Qualified Clinical Data Registries; Appropriations for the CDC National Neurological Conditions Surveillance System; Maintenance/expansion of Graduate Medical Education (GME); NIH funding including the BRAIN Initiative; Congressionally-Directed Medical Research Program funding; concussion related issues.
Client expense: Not reported · Firm income: $250,000
2018 · third_quarter · Pharmacy
S. 297, Increasing Competition in Pharmaceuticals Act (Collins-McCaskill) - prescription drug costs S. 974, CREATES Act (Leahy-Grassley) - access to generic drugs and biosimilars S. 1115, Making Pharmaceutical Markets More Competitive Act (Collins-McCaskill) - accelerated approval of generic therapies S. 1131, FAIR Drug Pricing Act (Baldwin-McCain) - transparency in prescription drug pricing S. 2553, Know the Lowest Price Act (Stabenow) - pharmacist-patient communications, S. 2554, Patient Right to Know Drug Prices Act (Collins) - pharmacist-patient communications, reporting of biosimilar pay-for-delay settlements S. 3194, Capping Prescription Costs Act (Warren) - capping prescription copays H.R. 749, Lower Drug Costs Through Competition Act (Schrader-Bilirakis) - prescription drug costs H.R. 1703, Medical Product Communication Act (Griffith) - off-label exchange of information H.R. 2026, Pharmaceutical Information Exchange Act (Guthrie) - pre-approval health care economic information to payors H.R. 2051, Fair Access for Safe and Timely Generics Act (McKinley-Welch) - access to generic drugs H.R. 2212, CREATES Act (Marino-Cicilline) - access to generic drugs and biosimilars H.R. 2439, FAIR Drug Pricing Act (Schakowsky) - transparency in prescription drug pricing H.R. 2562, Making Pharmaceutical Markets More Competitive Act (Kelly) - accelerated approval of generic therapies H.R. 2999, Patients' Access to Treatments Act (McKinley) - limiting cost sharing in specialty drug tiers H.R. 5247, Right to Try Act (Fitzpatrick) - use of unapproved investigational drugs by patients with life-threatening conditions H.R. 6142, Reducing Drug Waste Act (Doggett) - packaging of medications H.R. 6157, Defense-Labor-HHS-Education Appropriations Act (Granger) -pharmaceutical price transparency in DTC advertising H.R. 6340, Capping Prescription Costs Act (Rosen) - capping prescription copays H.R. 6478, Biosimilars Competition Act (Sarbanes) - reporting of pay-for-delay settlements H.R. 6576, Drug-Price Transparency in Communications Act (Schakowsky) - disclosure of drug prices in DTC advertising H.R. 6733, Know the Cost Act (Carter) - pharmacist-patient communications Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics; issues relating to opioids; issues relating to prescription drug price blueprint; issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
| Democratic |
| WI |
| James R. Langevin | Democratic | RI |
| Mark DeSaulnier | Democratic | CA |
| Matt Cartwright | Democratic | PA |
| Peter Welch | Democratic | VT |
| Ro Khanna | Democratic | CA |
| S 2582 |
115th |
| Related bill |
| HR 1776 | 115th | Related bill |
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $1,500,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of